IDiyas

For the Inventor, By the Inventor

East Lyme, CT, United States of America

Philip D Hammen

USPTO Granted Patents = 12

Average Co-Inventor Count = 2.0

ph-index = 4

Forward Citations = 39(Granted Patents)


Location History:

  • East Lyme, CT (US) (1976 - 1984)
  • East Haddam, CT (US) (1992 - 2004)

Company Filing History:

goldMedal12 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 1976-2004

Loading Chart...
12 patents (USPTO):Explore Patents
1. 6825327 - Process for preparing 4″-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives (2004-11-30),
2. 6410750 - Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid (2002-06-25),
3. 6013808 - Method of purifying carbazole ester precursors of (2000-01-11),
4. 5081118 - Benzothiazine dioxide derivatives (1992-01-14),
5. 4431828 - Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis (1984-02-14),
6. 4164514 - 2-Aminomethyleneindanone analgesic agents (1979-08-14),
7. 4117012 - 2-Aminomethyleneindanone analgesic agents (1978-09-26),
8. 4100347 - 3,4-Dihydro-2-methyl-4-oxo-2H-1,2-benzothiazine-3-carboxylic (1978-07-11),
9. 4064272 - 2-Aminomethyleneindanone analgesic agents (1977-12-20),
10. 4062844 - Process for preparing hypotensive (1977-12-13),
11. 4022836 - 2-Aminomethyleneindanone analgesic agents (1977-05-10),
12. 3950350 - Penam-dimethylsulfoxide complex (1976-04-13),

Title: The Innovative Journey of Philip D. Hammen

Introduction

Philip D. Hammen, an esteemed inventor based in East Lyme, Connecticut, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 12 patents, his work focuses on novel processes that have the potential to impact therapeutic treatments for various conditions.

Latest Patents

Among his latest patents, Philip has developed a process for preparing 4′-substituted-9-deoxo-9a-aza-9a-homoerythromycin A derivatives. Additionally, he has pioneered processes and intermediates for preparing 3(S)-[5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid. This innovative compound is particularly noteworthy as it can lead to the creation of indole 2-carboxamides and derivatives that possess glycogen phosphorylase inhibitory activity. Such advancements are crucial for the treatment of glycogen phosphorylase dependent diseases or conditions in humans.

Career Highlights

Philip is currently associated with Pfizer Corporation, a leading player in the pharmaceutical industry. His role in such a prestigious company underscores the value of his innovative work and the impact of his patents on current therapeutic strategies.

Collaborations

Throughout his career, Philip has collaborated with notable colleagues, including George M. Milne, Jr. and John L. Tucker. These partnerships have enriched his experience and enhanced the development of his patented inventions.

Conclusion

Philip D. Hammen exemplifies the spirit of innovation through his extensive work and contributions to the pharmaceutical landscape. With ongoing research and further advancements, his inventions hold promise for future breakthroughs in medical treatments, showcasing the invaluable role of inventors in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…